Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis. (9th March 2022)

• Record Type: Journal Article
• Authors: Auer, Michael; Hegen, Harald; Hotter, Anna; Löscher, Wolfgang; Berek, Klaus; Zinganell, Anne; Fava, Elena; Rhomberg, Paul; Deisenhammer, Florian; Di Pauli, Franziska
• Is Part Of: Journal of central nervous system disease. Volume 14(2022)
• Publication Date: 2022-03-09
• Subjects: ocrelizumab -- chronic inflammatory demyelinating polyneuropathy -- multiple sclerosis -- treatment -- off-label -- anti-CD20; Central nervous system -- Diseases -- Periodicals; Brain -- Diseases -- Periodicals; Spinal cord -- Diseases -- Periodicals; Central Nervous System Diseases; Brain Diseases; Brain -- Diseases; Central nervous system -- Diseases; Spinal cord -- Diseases; Electronic journals; Periodicals; Fulltext; Internet Resources; Periodicals; Periodicals; 573.863905
• DOI: 10.1177/11795735221084837
• Languages: English
• ISSNs: 1179-5735

Abstract

The chimeric anti-CD20 antibody rituximab has demonstrated good efficacy as an off-label treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), while the humanized anti-CD20 antibody ocrelizumab has been approved for treatment of multiple sclerosis (MS), whereas there is no evidence for its use in CIDP so far. We present a patient suffering from CIDP and MS, both refractory to standard treatment and both showing marked improvement on ocrelizumab. To the best of our knowledge, this is a unique report of CIDP with an almost full electrophysiological recovery on ocrelizumab which could be considered as a potential treatment option for refractory CIDP.